

Curriculum Vitae

Personal information **Aitana Calvo**

Work experience

1. Employer: Hospital Universitario Gregorio Marañón
 - Start date: 022014
 - End date:
 - Position: Attending physician in Oncology
 - Activities: Phase I medical coordinator, Attending Physician in Oncology, digestive tumours, especially gastro-esophageal tumours
 - Country: Spain
2. Employer: Hospital Doce de octubre
 - Start date: 122012
 - End date: 012014
 - Position: Attending physician in Oncology
 - Activities:
 - Country: Spain
3. Employer: Hospital de la Princesa
 - Start date: 052008
 - End date: 082012
 - Position: Attending physician in Oncology
 - Activities:
 - Country: Spain
4. Employer: Spanish Agency on Medicines
 - Start date: 052006
 - End date: 052008
 - Position: Clinical evaluation
 - Activities: Clinical evaluation, oncology
 - Country: Spain
5. Employer: Hospital Universitario Clínico San Carlos
 - Start date: 052002
 - End date: 052006
 - Position: Residency in Clinical Pharmacology
 - Activities:
 - Country: Spain

Education and training

1. Subject:
 - Start date: 022012
 - End date: 022016
 - Qualification: PhD Clinical Pharmacology
 - Organisation:
 - Country:
2. Subject: Universidad Complutense de Madrid
 - Start date: 091994
 - End date: 062000
 - Qualification: Medical Doctor
 - Organisation:
 - Country: Spain
3. Subject: hospital clinico san carlos
 - Start date: 052002
 - End date: 052006
 - Qualification: Specialisation in Clinical Pharmacology
 - Organisation:
 - Country: Spain
4. Subject: Hospital universitario de la princesa
 - Start date: 052008
 - End date: 052012
 - Qualification: Specialisation in Medical Oncology
 - Organisation:
 - Country: Spain

Additional information

Publications

□ Smyth et al. *J Clin Oncol* **44**, 343(2026) [44, Number 2 suppl DOI: 10.1200/JCO.2026.44.2_suppl.343](#); Soto et al. *J Clin Oncol* **44**, 167(2026) [Volume 44, Number 2 suppl DOI: 10.1200/JCO.2026.44.2_suppl.167](#) Ochstet et al. *J Clin Oncol* **43**, 2639(2025) [Volume 43, Number 16 suppl DOI: 10.1200/JCO.2025.43.16_suppl.2639](#)

Juric, D., ...Calvo, A., et al (2024). A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors. *Cancer Medicine*, 13(5). DOI: <https://doi.org/10.1002/cam4.6776> Valcarcel, S., ...Calvo, A., et al. (2023). Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry. *Journal of Cancer Research and Clinical Oncology*, 149(7), 4077-

4089. Jimenez-Fonseca, P., Calvo, A et al (2023). The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy. *Therapeutic advances in medical oncology*, 15, 17588359231157641. [Felip, E., ... Calvo, A et al \(2022\). First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 \(PD-1\) inhibitor cetrelimab \(JNJ-63723283\) in patients with advanced cancers. *Cancer Chemotherapy and Pharmacology*, 89\(4\), 499-514.](#) Hecht JR... Calvo A, et al. A phase 1b/2, multicenter, openlabel trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into primary and metastatic liver tumors alone and in combination with pembrolizumab (pembro) (MASTERKEY_318). *J Clin Oncol* 2018 36:15_suppl, TPS3105_TPS3105 □ Bordonaro R, Calvo A, et al. Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab: Results of the expansion part of a phase I study in patients with metastatic colorectal cancer. DOI: 10.1200/JCO.2020.38.4_suppl.140 *Journal of Clinical Oncology* 38, no. 4_suppl (February 01, 2020) 140_140. □ Argilés G, André T, Hollebecque A, Calvo A, Dahan L, Cervantes A, Leger C, Amellal N, Fougeray R, Tabernero J. Phase I dose_escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer. *Eur J Cancer*. 2019 May;112:12_19. doi: 10.1016/j.ejca.2019.01.101. Epub 2019 Mar 16. □ Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. *N Engl J Med* 2019; 381:1632_1643; DOI: 10.1056/NEJMoa1908075 □ Rutkowski P, Felip E, Moreno V, Trigo JM, Calvo A et al. Anti_PD_1 antibody cetrelimab (JNJ_63723283) in patients with advanced cancers: Updated phase I/II study. DOI: 10.1200/JCO.2019.37.8_suppl.31 *Journal of Clinical Oncology* 37, no. 8_suppl (March 10, 2019) 31_31. □ Marzal_Alfaro MB, Escudero_Vilaplana V, Rodríguez_González CG, González_Haba E, Calvo A, Osorio S, Iglesias_Peinado I, Herranz A, Sanjurjo M. Error Detection and Cost Savings With an Image-Based Workflow Management System Connected to a Computerized Prescription Order Entry Program for Antineoplastic Compounding. *J Patient Saf*. 2019 Mar 6. doi: 10.1097/PTS.0000000000000591. [Epub ahead of print] □ Calvo A, Joensuu H, Sebastian M, Naing A, Bang Y, Martin M et al. Phase Ib/II study of lacnatumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors. *J Clin Oncol* 36, 2018 (suppl; abstr 3014) □ Hong DS, Schoffski P, Calvo A, Sarantopoulos J, Ochoa De Olza M, Carvajal R et al. Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies. *J Clin Oncol* 36, 2018 (suppl; abstr 3012) □ Terleira_Fernández A, Calvo Ferrándiz A y Vargas Castrillón. Interacciones de los fármacos con otros fármacos, alimentos y con pruebas de laboratorio. En: Lorenzo, Moreno, Leza, Lizasoain, Moro y Portolés, editores. Velázquez. *Farmacología Básica y Clínica*. 19ª edición. 2018. □ Hollebecque A, Calvo A, Andre T, Argiles G, Cervantes A, Leger C. Phase I multicenter, openlabel study to establish the maximum tolerated dose (MTD) of trifluridine/tipiracil (TAS_102) and oxaliplatin combination in patients (pts) with metastatic colorectal cancer (mCRC). *J Clin Oncol* 36, 2018 (suppl 4S; abstr 816) □ Garcia Alfonso P, Garcia G, Gallego I, Peligros I, Corcuera A, Puente B, Lobo M, Ruperez A, Aguado G, Sandoval C, Blanco_Codesido M, Calvo A et al. Prognostic and predictive factors in metastatic colorectal cancer. *J Clin Oncol* 36, 2018 (suppl 4S; abstr 690) □ Blanco Codesido M, Calvo Ferrándiz A, López_Tarruella S, Alvarez R, Jerez Y, Pérez S et al. Validation of the Royal Marsden Hospital (RMH) prognostic score on an enriched early treatment line cohort for phase I trial patients. *Annals of Oncology*, Volume 28, Issue suppl_5, 1 September 2017, mdx367.041, <https://doi.org/10.1093/annonc/mdx367.041> □ Marquez_Rodas I, Rodríguez_Ruiz M, López_Tarruella S, Perez_Gracia JL, Ponz_Sarvisse M, Alvarez R, de Miguel E, Jerez Y, Calvo A et al. Safety and immunobiological activity of intratumoral (IT) double stranded RNA (dsRNA) BO_112 in solid malignancies: first in human clinical trial. *Annals of Oncology* (2017) 28 (suppl_5): v605_v649. 10.1093/annonc/mdx440 □ Martín M, Calvo A. et al. New clinical trials regulation in Spain: analysis of royal decree 1090/2015. *Clin Transl Oncol* (2016). doi:10.1007/s12094_016_1550_9 □ Marquez I, Luque S, Sanz M, Peligros M, Flores C, Mata C, Die Trill M, Lizarraga S, Rincon S, Bueno O, Lopez_Tarruella S, Jerez Y, Muñoz A, Calvo A et al. First one thousand families: Our multidisciplinary experience in the heredo_familial cancer unit from a Spanish University Hospital. DOI: 10.1200/jco.2015.33.15_suppl.1556 *Journal of Clinical Oncology* 33, no. 15_suppl (May 2015) 1556_1556. □ Bayo J, Fonseca P, Hernando S, Servitja E, Calvo A et al. Chemotherapy_induced nausea and vomiting: pathophysiology and therapeutic principles. *Clin Transl Oncol* (2012) 14:413_422 □ Ruiz_Antoráz B, Agustí A, Vallano A, Danés I, Riba N et al. for the Spanish Group for the Study of the Use of Nonspecific Intravenous Human Immunoglobulins (SUIG). Use Of Nonspecific Intravenous Human Immunoglobulins In Spanish Hospitals; Need For A Hospital Protocol. *European Journal of Clinical Pharmacology*. *Eur J Clin Pharmacol* (2010) 66:633-641 □ Portolés A, Prieto E, Calvo A, Laredo L, Fernández N, Vargas E. Truncated area under the urinary excretion rate curve in the evaluation of alendronate bioequivalence after a single dose in healthy volunteers. *Arzneimittelforschung*. 2009; 59(8):397_402. □ Terleira A, Calvo A y Moreno A. Interacciones de los fármacos con otros fármacos, alimentos y con pruebas de laboratorio. En: Lorenzo, Moreno, Leza, Lizasoain, Moro y Portolés, editores. Velázquez. *Farmacología Básica y Clínica*. 18ª edición. 2009. □ Portolés A, Calvo A, Terleira A, Laredo L, Resplandy G, Gorostiaga C, Moreno A. Lack of Pharmacokinetic Interaction Between Omeprazole or Lansoprazole and Ivabradine in Healthy Volunteers: An Open_Label, Randomized, Crossover, Pharmacokinetic Interaction Clinical Trial. *Journal of Clinical Pharmacology*, 2006; 46:1195_1203. □ Portolés A, Terleira A, Calvo A, Martínez I, Resplandy G. Effects of Hypericum perforatum on Ivabradine Pharmacokinetics in Healthy Volunteers: An Open_Label, Pharmacokinetic Interaction Clinical Trial. *Journal of Clinical Pharmacology*, 2006; 46:1188_1194. □ Bayo J, Fonseca P, Hernando S, Servitja E, Calvo A et al. Chemotherapy_induced nausea and vomiting: pathophysiology and therapeutic principles. *Clin Transl Oncol* (2012) 14:413_422

Projects

Phase I Unit Medical Coordinator.

Memberships

□ Member of the Committee for Medicinal Products for Human Use at the Spanish Agency on Medicines. □ Scientific Secretary at the Spanish Society of Medical Oncology (2016_2020). □ Member of the Translational Research in Oncology of the Oncology Institute of the Hospital General Universitario Gregorio Marañón. Member of the Ethics Committee of Clinical Investigation at the Hospital Universitario Gregorio Marañón de Madrid □ Member of the Quality Commission of the Oncology Department of the Hospital General Universitario Gregorio Marañón. □ Member of the Mortality Commission at the Hospital Universitario Gregorio Marañón de Madrid. □ Member of the CAR_T committee del Hospital General Univesitario Gregorio Marañón. □ Teacher of diverse Masters Programs in public and private institutions. □ Member of the Spanish Society of Clinical Oncology and of the Spanish Society in Clinical Pharmacology. □ Scientific Evaluation for the Investigation Grants of the Spanish Ministry of Health. □ PhD grant for the program in Molecular Biology and Biochemistry in the University of Wesleyan, Connecticut, USA. Student internship at the René Descartes University in Paris, at the Lausanne University Hospital (CHUV), the Hospital Policlinico de Palermo and the University of Utrecht.

Other Relevant Information